Sprint Bioscience starts a diabetes program

Sprint Bioscience has signed a collaboration agreement with the Lundberg Laboratory for Diabetes Research at Gothenburg University in which Sprint Bioscience will develop drug candidates against a new target protein that is central to the development of type 2 diabetes. Sprint Bioscience has in fact already identified series of substances and a chemistry program is in place. The molecules will be evaluated in disease models developed for diabetes research at the Lundberg Laboratory. The aim is to initiate out-licensing of the project in 2016, when the identity of the target molecules will